The goal will be to increase awareness about CSL Behring Canada and to gain clarity on process and implementation steps required to administer gene therapy for the treatment of hemophilia B at a hospital center of excellence.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Hospitals
|
The goal will be to increase awareness about CSL Behring Canada as an innovative biotherapeutics company. Additionally there will be discussions about British Columbia's anticipated policies and procedures to provide patient access for new novel therapies including gene therapy for the treatment of Hemophilia-B.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|